Loading...
Remembering the host in tuberculosis drug development
Frank, D.J Horne, D.J Dutta, N.K Shaku, M.T Madensein, R Hawn, T.R Steyn, A.J.C Karakousis, P.C Kana, B.D Meintjes, G
Frank, D.J
Horne, D.J
Dutta, N.K
Shaku, M.T
Madensein, R
Hawn, T.R
Steyn, A.J.C
Karakousis, P.C
Kana, B.D
Meintjes, G
Citations
Altmetric:
Abstract
New therapeutics to augment current approaches and shorten treatment duration are of critical importance for combating tuberculosis (TB), especially those with novel mechanisms of action to counter the emergence of drug-resistant TB. Host-directed therapy (HDT) offers a novel strategy with mechanisms that include activating immune defense mechanisms or ameliorating tissue damage. These and related concepts will be discussed along with issues that emerged from the workshop organized by the Stop TB Working Group on New Drugs, held at the Gordon Research Conference for Tuberculosis Drug Development in Lucca, Italy in June 2017, titled "Strategic Discussion on Repurposing Drugs & Host Directed Therapies for TB." In this review, we will highlight recent data regarding drugs, pathways, and concepts that are important for successful development of HDTs for TB.
Description
Date
2019-04-19
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford Academic
Collections
Research Projects
Organizational Units
Journal Issue
Keywords
drug development,host-directed therapy,macrophage,meningitis,tuberculosis
Citation
Frank DJ, Horne DJ, Dutta NK, Shaku MT, Madensein R, Hawn TR, Steyn AJC, Karakousis PC, Kana BD, Meintjes G, Laughon B, Tanvir Z. Remembering the Host in Tuberculosis Drug Development. J Infect Dis. 2019 Apr 19;219(10):1518-1524. doi: 10.1093/infdis/jiy712.